Novo Nordisk: Q3 results disappoint

(CercleFinance.com) - Novo Nordisk, the world's leader in diabetes treatment, has reported Q3 operating profit slightly below expectations due to the impact of Covid, which forced some patients to delay the start of their treatments.


The Danish group's operating profit for the past three months amounted to 12.8 billion Danish kronor (about 1.72 billion euros), falling short of the consensus of 13.1 billion Danish kronor.

Over the first nine months of the year, sales increased by 6% to 94.8 billion Danish kronor, with operating profit also up 6% to 42.9 billion Danish kronor.

In a statement, the group confirmed its full-year targets, including between 5% and 8% growth in sales and operating profit at constant exchange rates.

The Novo Nordisk share is down over 1.5% on the Copenhagen Stock Exchange following these results, which analysts were disappointed by.


Copyright (c) 2020 CercleFinance.com. All rights reserved.